Linda Chapdeleine Mekue Mouafo, Hélène Péré, Angélique Ndjoyi-Mbiguino, Donato Koyalta, Jean De Dieu Longo, François-Xavier Mbopi-Kéou, Coumba Toure Kane, Laurent Bélec
{"title":"致编辑:ViroSeq®HIV-1基因分型系统v2.0在中非的表现","authors":"Linda Chapdeleine Mekue Mouafo, Hélène Péré, Angélique Ndjoyi-Mbiguino, Donato Koyalta, Jean De Dieu Longo, François-Xavier Mbopi-Kéou, Coumba Toure Kane, Laurent Bélec","doi":"10.2174/1874613601509010009","DOIUrl":null,"url":null,"abstract":"<p><p>Resistance genotypes in pol gene of HIV-1 were obtained by the ViroSeq(®) HIV-1 Genotyping System v2.0 (Celera Diagnostics, Alameda, CA, USA) in 138 of 145 (95%) antiretroviral treatment-experienced adults in virological failure living in Central Africa (Cameroon, Central African Republic, Chad, Gabon). HIV-1 group M exhibited broad genetic diversity. Performance of the 7 ViroSeq(®) sequencing primers showed high failure rate, from 3% to 76% (D: 76%; F: 17%; A and H: 15%; G and B: 4%; C: 3%). These findings emphasize the need of updating the ViroSeq(®) HIV-1 genotyping system for non-B subtypes HIV-1. </p>","PeriodicalId":515834,"journal":{"name":"The Open AIDS Journal","volume":"9 ","pages":"9-13"},"PeriodicalIF":0.0000,"publicationDate":"2015-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6d/93/TOAIDJ-9-9.PMC4353127.pdf","citationCount":"7","resultStr":"{\"title\":\"LETTER TO THE EDITOR Performance of the ViroSeq® HIV-1 Genotyping System v2.0 in Central Africa.\",\"authors\":\"Linda Chapdeleine Mekue Mouafo, Hélène Péré, Angélique Ndjoyi-Mbiguino, Donato Koyalta, Jean De Dieu Longo, François-Xavier Mbopi-Kéou, Coumba Toure Kane, Laurent Bélec\",\"doi\":\"10.2174/1874613601509010009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Resistance genotypes in pol gene of HIV-1 were obtained by the ViroSeq(®) HIV-1 Genotyping System v2.0 (Celera Diagnostics, Alameda, CA, USA) in 138 of 145 (95%) antiretroviral treatment-experienced adults in virological failure living in Central Africa (Cameroon, Central African Republic, Chad, Gabon). HIV-1 group M exhibited broad genetic diversity. Performance of the 7 ViroSeq(®) sequencing primers showed high failure rate, from 3% to 76% (D: 76%; F: 17%; A and H: 15%; G and B: 4%; C: 3%). These findings emphasize the need of updating the ViroSeq(®) HIV-1 genotyping system for non-B subtypes HIV-1. </p>\",\"PeriodicalId\":515834,\"journal\":{\"name\":\"The Open AIDS Journal\",\"volume\":\"9 \",\"pages\":\"9-13\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-02-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6d/93/TOAIDJ-9-9.PMC4353127.pdf\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Open AIDS Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1874613601509010009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2015/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Open AIDS Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874613601509010009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
LETTER TO THE EDITOR Performance of the ViroSeq® HIV-1 Genotyping System v2.0 in Central Africa.
Resistance genotypes in pol gene of HIV-1 were obtained by the ViroSeq(®) HIV-1 Genotyping System v2.0 (Celera Diagnostics, Alameda, CA, USA) in 138 of 145 (95%) antiretroviral treatment-experienced adults in virological failure living in Central Africa (Cameroon, Central African Republic, Chad, Gabon). HIV-1 group M exhibited broad genetic diversity. Performance of the 7 ViroSeq(®) sequencing primers showed high failure rate, from 3% to 76% (D: 76%; F: 17%; A and H: 15%; G and B: 4%; C: 3%). These findings emphasize the need of updating the ViroSeq(®) HIV-1 genotyping system for non-B subtypes HIV-1.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
